Etira

Etira is a preclinical-stage biotechnology company focused on developing a new class of small molecule therapeutics for hard-to-treat cancers. The company's lead candidate, ERX-41, targets the protein Lysosomal acid lipase A (LIPA) to induce lethal endoplasmic reticulum (ER) stress specifically in cancer cells while sparing healthy tissue. This novel mechanism of action shows promise across several aggressive malignancies, including triple-negative breast cancer, glioblastoma, and pancreatic cancer. Etira was founded by researchers from UT Southwestern Medical Center and the University of Texas at Dallas to translate these breakthrough discoveries into clinical treatments. The company is currently advancing its lead program through IND-enabling studies to address significant unmet needs in oncology.